Readers of this blog may recall that in the past year, I wrote extensively about the U.S. Supreme Court case of Oil States v. Greene’s Energy. But I paid little attention to another important case decided around the same time: SAS Institute v. Iancu. Oil States centered on whether the USPTO’s inter partes review
IPR

Mohawk Tribe v. Mylan Highlights USPTO Constraints
By Kyle Kroll on
Credit: Federal Circuit (what it looks like to argue there)
One week ago, the Federal Circuit Court of Appeals issued its decision in Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals, Inc., 18-1638 (Fed. Cir. July 20, 2018)–by all accounts, one of this decade’s most important decisions concerning the America Invents Act and the…
Patent IPRs and Allergan’s Sovereign Immunity Defense
By Duets Guest Blogger on
— Jessica Gutierrez Alm, Attorney
In an age of rising healthcare costs, pharmaceutical companies can be an easy target in calls for patent reform. Patent protection helps drug manufacturers recoup their investment in developing the new drug,. It also prevents generic manufacturers from releasing the same drug formulation at lower cost. The Hatch-Waxman Act provides…